The Polish Ministry of Health faced intense scrutiny during the 35th Economic Forum in Karpacz after officials failed to present the long-awaited state drug policy document, displaying instead a multimedia presentation containing artificial intelligence artifacts and shifting dates.
According to reports, the last official drug policy strategy in Poland covered a timeframe running through 2022. The Ministry of Health subsequently spent years preparing a successor document, leaving the pharmaceutical sector awaiting a strategic roadmap for the market. When officials announced that the new strategy would debut at the economic forum in Karpacz, industry stakeholders expected a comprehensive plan covering the years 2026 to 2030, based on initial ministry indications.
Instead, Deputy Health Minister Katarzyna Kacperczyk and a departmental director delivered a multimedia presentation rather than a finalized document, according to the available reports. The first slide of the display indicated a different operational timeline of 2027 to 2032, highlighting discrepancies in the ministry’s scheduling. Furthermore, representatives spent an hour reading text generated by artificial intelligence software that contained grammatical errors and stray foreign terms, such as the Italian word “tanto” appearing instead of the Polish word “zarówno.”
Ministry Strategy Goals and Expert Consultations
According to government communications, the upcoming strategy—officially designated as the State Drug Policy for 2027–2032—aims to build upon a previous framework implemented between 2018 and 2022. Deputy Minister Katarzyna Kacperczyk emphasized during discussions at the forum that the initiative involves an open dialogue with medical professionals, economic local governments, and health system institutions to look five, ten, and fifteen years ahead. Conceptual work on the strategy began in October 2025 through consultations involving the Ministry of Health, the National Health Fund (NFZ), the Chief Pharmaceutical Inspectorate (GIF), the Medical Research Agency (ABM), the e-Health Center, and the Agency for Health Technology Assessment and Tariff System (AOTMiT).
According to reporting from Radio ZET, the strategy outlines seven primary directions aimed at improving drug availability, controlling public spending, and boosting the domestic pharmaceutical industry. Plans include integrating digital data across institutions like the NFZ and GIF to utilize AI tools for anticipating drug shortages and monitoring therapeutic outcomes. Additional objectives involve organizing a formalized list of critical medications grouped by risk factors—such as armed conflict or supply disruptions—in cooperation with the Ministry of National Defense (MON) and military medical facilities.
Did You Know? According to ministry data cited by Radio ZET, patients in Poland returned over 750 tons of expired and unused medications to 3344 participating pharmacies in 2025 alone, prompting new goals to reduce pharmaceutical waste and streamline prescription management.
Future Timelines and Administrative Next Steps
Ministry experts provided conflicting delivery dates during their presentation in Karpacz, stating initially that the formal document would arrive at the end of September while concluding their remarks by suggesting early October. Industry observers note that a possible next step involves the formal publication of the finalized 2027–2032 strategy text following the conclusion of ongoing stakeholder consultations.
Analysts suggest that if the ministry meets its updated timeline, the detailed regulatory framework could soon provide clarity on whether state support will favor foreign manufacturers of advanced therapies or domestic producers of more affordable, established medications. Until the physical text is released, however, market participants continue to operate in a strategic vacuum.
Frequently Asked Questions
What timeframe does the new state drug policy cover? According to official ministry materials presented in Karpacz, the upcoming strategy is planned for the years 2027 to 2032, succeeding the previous framework that ran through 2022.
Which public institutions are involved in developing the strategy? The planning process incorporates data and cooperation from the National Health Fund (NFZ), the Chief Pharmaceutical Inspectorate (GIF), the Medical Research Agency (ABM), the e-Health Center, and the Agency for Health Technology Assessment and Tariff System (AOTMiT).
How does the ministry plan to handle critical medication shortages? The strategy proposes creating an organized list of critical drugs categorized by threat types, such as military conflict or supply disruptions, with input from the Ministry of National Defense and military medical institutions.
How will the upcoming strategy impact local manufacturers versus international firms?
Worth a look